-
1
-
-
85008260747
-
Terminology for biosimilars-A confusing minefield
-
Thorpe R, Wadhwa M: Terminology for biosimilars-a confusing minefield. GaBI J 2012;1:132-134.
-
(2012)
GaBI J
, vol.1
, pp. 132-134
-
-
Thorpe, R.1
Wadhwa, M.2
-
2
-
-
84871639510
-
Opportunities and challenges for biosimilars: What's on the horizon in the global insulin market?
-
Rotenstein LS, Ran N, Shivers JP, et al.: Opportunities and challenges for biosimilars: what's on the horizon in the global insulin market? Clin Diabetes 2012;30:138-150.
-
(2012)
Clin Diabetes
, vol.30
, pp. 138-150
-
-
Rotenstein, L.S.1
Ran, N.2
Shivers, J.P.3
-
3
-
-
84868017986
-
The emergence of biosimilar insulin preparations: A cause for concern?
-
Owens DR, Landgraf W, Schmidt A, et al.: The emergence of biosimilar insulin preparations: a cause for concern? Diabetes Technol Ther 2012;14:989-996.
-
(2012)
Diabetes Technol Ther
, vol.14
, pp. 989-996
-
-
Owens, D.R.1
Landgraf, W.2
Schmidt, A.3
-
4
-
-
84863803301
-
Biosimilar insulins
-
Heinemann L: Biosimilar insulins. Expert Opin Biol Ther 2012;12:1009-1016.
-
(2012)
Expert Opin Biol Ther
, vol.12
, pp. 1009-1016
-
-
Heinemann, L.1
-
5
-
-
84881356882
-
Biosimilar insulins: Opportunities and challenges
-
Gough S: Biosimilar insulins: opportunities and challenges. Pract Diabetes 2013;30:146-148.
-
(2013)
Pract Diabetes
, vol.30
, pp. 146-148
-
-
Gough, S.1
-
6
-
-
78049362302
-
-
Expert Committee on Biological Standardization, Geneva, 19-23 October. (accessed January 27, 2014)
-
World Health Organization: Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Expert Committee on Biological Standardization, Geneva, 19-23 October 2009. www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf (accessed January 27, 2014).
-
(2009)
Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)
-
-
-
9
-
-
84863435547
-
The advent of biosimilar therapies in rheumatology-"O brave new world."
-
Scheinberg MA, Kay J: The advent of biosimilar therapies in rheumatology-"O brave new world." Nat Rev Rheumatol 2012;8:430-436.
-
(2012)
Nat Rev Rheumatol
, vol.8
, pp. 430-436
-
-
Scheinberg, M.A.1
Kay, J.2
-
10
-
-
33644952525
-
-
(accessed August 13, 2014)
-
European Medicines Agency: EMA Guideline on Similar Biological Medicinal Products. 2005. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003517.pdf (accessed August 13, 2014).
-
(2005)
EMA Guideline on Similar Biological Medicinal Products
-
-
-
11
-
-
33644952525
-
-
Draft. (accessed August 13, 2014)
-
European Medicines Agency: EMA Guideline on Similar Biological Medicinal Products. Draft. 2013. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/05/WC500142978.pdf (accessed August 13, 2014).
-
(2013)
EMA Guideline on Similar Biological Medicinal Products
-
-
-
17
-
-
85082156098
-
Decreto por el que se Reforman y Adicionan Diversas Disposiciones del Reglamento de Insumos Para la Salud
-
(accessed August 13, 2014)
-
Official Journal of the Federation: Decreto por el que se Reforman y Adicionan Diversas Disposiciones del Reglamento de Insumos Para la Salud. 2011. http://dof.gob.mx/nota-detalle.php?codigo=5214882&fecha=19/10/2011 (accessed August 13, 2014).
-
(2011)
Official Journal of the Federation
-
-
-
18
-
-
85082149634
-
-
Version 1.1. (accessed August 13, 2014)
-
Saudi Food & Drug Authority: Guidelines on Biosimilars. Version 1.1. 2010. http://old.sfda.gov.sa/NR/rdonlyres/CB28C6AF-79CD-4412-8801-35AEDEED0183/0/Guidelines onbiosimilars-v11.pdf (accessed August 13, 2014).
-
(2010)
Guidelines on Biosimilars
-
-
-
19
-
-
85082158718
-
-
(accessed August 13, 2014)
-
Jordan Food & Drug Administration: Guidance for Registration of Biosimilars. 2013. www.jfda.jo/Download/News/239-530.pdf (accessed August 13, 2014).
-
(2013)
Guidance for Registration of Biosimilars
-
-
-
20
-
-
85082156013
-
-
(accessed August 13, 2014)
-
Egyptian Ministry of Health, Central Administration for Pharmaceutical Affairs, General Registration Department, Department of Biological Products Registration: Draft Guideline for Registration of Biosimilar Products. 2012. www.eda.mohp.gov.eg/Download/Docs/Final%20biosimilar %20guideline.pdf (accessed August 13, 2014).
-
(2012)
Draft Guideline for Registration of Biosimilar Products
-
-
-
21
-
-
84875477769
-
-
(accessed August 13, 2014)
-
Government of India, Department of Biotechnology, Ministry of Science and Technology, Central Drugs Standard Control Organization, Ministry of Health and Family Welfare: Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India. 2012. http://cdsco.nic.in/writereaddata/Bio%20Similar%20Guideline.pdf (accessed August 13, 2014).
-
(2012)
Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India
-
-
-
22
-
-
84856779186
-
-
(accessed August 13, 2014)
-
Korean Food and Drug Administration: Guidelines on the Evaluation of Biosimilar Products. 2010. www.mfds.go.kr/jsp/common/download.jsp?fileinfo=S∗1∗%B5%BF%B5%EE%BB%FD%B9%B0%C0%C7%BE%E0%C7%B0%20% C6%F2%B0%A1%20%B0%A1%C0%CC%B5%E5%B6%F3%C0%CE%20(%BF%B5%B9%AE).pdf∗e9a03e5980ec4520b888e54dbf6ee908∗pdf∗/files/upload/1/TB-F-INFODATA/13325/e9a03e5980ec4520b888e54dbf6ee908∗265678∗2012:08:29%2016:10:23 (accessed August 13, 2014).
-
(2010)
Guidelines on the Evaluation of Biosimilar Products
-
-
-
24
-
-
84928475369
-
-
Version 1.0, July (accessed August 13, 2014)
-
Therapeutic Goods Administration, Department of Health, Australian Government: Evaluation of Biosimilars. Version 1.0, July 2013. www.tga.gov.au/pdf/pm-argpm-biosimilars.pdf (accessed August 13, 2014).
-
(2013)
Evaluation of Biosimilars
-
-
-
25
-
-
85082149622
-
-
(accessed August 13, 2014)
-
MEDSAFE New Zealand Medicines and Medical Devices Safety Authority: Medicines: Biosimilars. 2013. www.medsafe.govt.nz/profs/RIss/Biosimilars.asp (accessed August 13, 2014).
-
(2013)
Medicines: Biosimilars
-
-
-
29
-
-
84926062530
-
-
[press release]. August 18, (accessed August 31, 2014)
-
Boehringer Ingelheim: FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (Insulin Glargine Injection) [press release]. August 18, 2014. http://us.boehringer-ingelheim.com/news-events/press-releases/press-release-archive/2014/08-18-14-fda-grants-tentativeapproval-lilly-boehringer-ingelheim-basaglar-insulin-glargineinjection.html (accessed August 31, 2014).
-
(2014)
FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (Insulin Glargine Injection)
-
-
-
30
-
-
84873849289
-
Regulatory stratergies for biosimilars in regulated and emerging markets
-
Reddy S, Balamuralidhara V, Pramod Kumar TM, et al.: Regulatory stratergies for biosimilars in regulated and emerging markets. Pharma Times 2013;45:11-14.
-
(2013)
Pharma Times
, vol.45
, pp. 11-14
-
-
Reddy, S.1
Balamuralidhara, V.2
Pramod Kumar, T.M.3
-
31
-
-
84946604676
-
-
November 14, (accessed January 8, 2015)
-
GaBI Online: China Releases Draft Biosimilars Guidance. November 14, 2014. www.gabionline.net/Guidelines/Chinareleases-draft-biosimilars-guidance (accessed January 8, 2015).
-
(2014)
China Releases Draft Biosimilars Guidance
-
-
-
32
-
-
21444442363
-
Biosimilar epoetins: An analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins
-
Combe C, Tredree RL, Schellekens H: Biosimilar epoetins: an analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005; 25:954-962.
-
(2005)
Pharmacotherapy
, vol.25
, pp. 954-962
-
-
Combe, C.1
Tredree, R.L.2
Schellekens, H.3
-
36
-
-
67549112400
-
Insights from the liraglutide clinical development program-The liraglutide effect and action in diabetes (LEAD) studies
-
McGill JB: Insights from the Liraglutide Clinical Development Program-the Liraglutide Effect and Action in Diabetes (LEAD) studies. Postgrad Med 2009;121: 16-25.
-
(2009)
Postgrad Med
, vol.121
, pp. 16-25
-
-
McGill, J.B.1
-
37
-
-
85082149613
-
-
Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 Amending, as Regards Pharmacovigilance, Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use. (accessed August 13, 2014)
-
Official Journal of the European Union: Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 Amending, as Regards Pharmacovigilance, Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use. 2010. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF (accessed August 13, 2014).
-
(2010)
Official Journal of the European Union
-
-
-
38
-
-
80051570290
-
Biosimilar peptides: Need for pharmacovigilance
-
Joshi SR: Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India 2011;59(Suppl):44-47.
-
(2011)
J Assoc Physicians India
, vol.59
, pp. 44-47
-
-
Joshi, S.R.1
-
39
-
-
68649124703
-
-
Brussels: European Generic Medicines Association
-
European Generic Medicines Association: EGA Handbook on Biosimilar Medicines. Brussels: European Generic Medicines Association, 2008.
-
(2008)
EGA Handbook on Biosimilar Medicines
-
-
-
40
-
-
79961107025
-
-
(accessed August 13, 2014)
-
U.S. Food and Drug Administration: Biologics Price Competition and Innovation (BPCI) Act. 2009. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ucm216146.pdf (accessed August 13, 2014).
-
(2009)
Biologics Price Competition and Innovation (BPCI) Act
-
-
-
44
-
-
84946542353
-
-
(accessed August 13, 2014)
-
European Medicines Agency: Withdrawal Assessment Report for Insulin Human Rapid Marvel. 2008. www.ema.europa.eu/docs/en-GB/document-library/Application-withdrawal-assessment-report/2010/01/WC500067086.pdf (accessed August 13, 2014).
-
(2008)
Withdrawal Assessment Report for Insulin Human Rapid Marvel
-
-
-
45
-
-
84946542353
-
-
(accessed August 13, 2014)
-
European Medicines Agency: Withdrawal Assessment Report for Insulin Human Long Marvel. 2008. www.ema.europa.eu/docs/en-GB/document-library/Application-withdrawal-assessment-report/2010/01/WC500067170.pdf (accessed August 13, 2014).
-
(2008)
Withdrawal Assessment Report for Insulin Human Long Marvel
-
-
-
46
-
-
84946542353
-
-
(accessed August 13, 2014)
-
European Medicines Agency: Withdrawal Assessment Report for Insulin Human 30/70 Mix Marvel. 2008. www.ema.europa.eu/docs/en-GB/document-library/Application-withdrawal-assessment-report/2010/01/WC500067169.pdf (accessed August 13, 2014).
-
(2008)
Withdrawal Assessment Report for Insulin Human 30/70 Mix Marvel
-
-
-
48
-
-
47549097069
-
Epoetinassociated pure red cell aplasia: Past, present, and future considerations
-
McKoy JM, Stonecash RE, Cournoyer D, et al.: Epoetinassociated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;48:1754-1762.
-
(2008)
Transfusion
, vol.48
, pp. 1754-1762
-
-
McKoy, J.M.1
Stonecash, R.E.2
Cournoyer, D.3
-
49
-
-
69449095403
-
Biosimilar therapeutics-what do we need to consider?
-
Schellekens H: Biosimilar therapeutics-what do we need to consider? NDT Plus 2009;2(Suppl 1):i27-i36.
-
(2009)
NDT Plus
, vol.2
, pp. i27-i36
-
-
Schellekens, H.1
-
50
-
-
71649087076
-
Heterogeneity of commercial recombinant human growth hormone (r-hGH) preparations containing a thioether variant
-
Lispi M, Datola A, Bierau H, et al.: Heterogeneity of commercial recombinant human growth hormone (r-hGH) preparations containing a thioether variant. J Pharm Sci 2009;98:4511-4524.
-
(2009)
J Pharm Sci
, vol.98
, pp. 4511-4524
-
-
Lispi, M.1
Datola, A.2
Bierau, H.3
-
51
-
-
51249099154
-
The interpretation of glucose clamp studies of long-acting insulin analogues: From physiology to marketing and back
-
Swinnen SG, Holleman F, DeVries JH: The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia 2008; 51:1790-1795.
-
(2008)
Diabetologia
, vol.51
, pp. 1790-1795
-
-
Swinnen, S.G.1
Holleman, F.2
DeVries, J.H.3
-
52
-
-
84928576980
-
Similar efficacy and safety with LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T1DM: The ELEMENT 1 study
-
[abstract 69-OR]
-
Blevins T, Dahl D, Rosenstock J, et al.: Similar efficacy and safety with LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T1DM: the ELEMENT 1 study [abstract 69-OR]. Diabetes 2014; 63(Suppl 1):A19.
-
(2014)
Diabetes
, vol.63
, pp. A19
-
-
Blevins, T.1
Dahl, D.2
Rosenstock, J.3
-
53
-
-
84928540283
-
Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T1DM or T2DM
-
[abstract 70-OR]
-
Deeg M, Ilag L, Huster WJ, et al.: Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T1DM or T2DM [abstract 70-OR]. Diabetes 2014;63(Suppl 1):A19.
-
(2014)
Diabetes
, vol.63
, pp. A19
-
-
Deeg, M.1
Ilag, L.2
Huster, W.J.3
-
54
-
-
84937813025
-
Comparative pharmacokinetics (PK) and pharmacodynamics (PD) of LY2963016 insulin glargine and EU- and U.S.-approved versions of Lantus® insulin glargine in healthy subjects
-
[abstract 889-P]
-
Linnebjerg H, Chen Quin Lam E, Seger ME, et al.: Comparative pharmacokinetics (PK) and pharmacodynamics (PD) of LY2963016 insulin glargine and EU- and U.S.-approved versions of Lantus® insulin glargine in healthy subjects [abstract 889-P]. Diabetes 2014;63(Suppl 1): A227.
-
(2014)
Diabetes
, vol.63
, pp. A227
-
-
Linnebjerg, H.1
Chen Quin-Lam, E.2
Seger, M.E.3
-
55
-
-
84928572271
-
Duration of action of 2 insulin glargine products, LY2963016 and Lantus®, in subjects with type 1 diabetes mellitus (T1DM)
-
[abstract 891-P]
-
Heise T, Zhang X, Chen Quin Lam E, et al.: Duration of action of 2 insulin glargine products, LY2963016 and Lantus®, in subjects with type 1 diabetes mellitus (T1DM) [abstract 891-P]. Diabetes 2014;63(Suppl 1):A228.
-
(2014)
Diabetes
, vol.63
, pp. A228
-
-
Heise, T.1
Zhang, X.2
Chen Quin-Lam, E.3
-
56
-
-
84928547217
-
Similar efficacy and safety with LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T2DM: The ELEMENT 2 study
-
[abstract 64-OR]
-
Rosenstock J, Hollander P, Bhargava A, et al.: Similar efficacy and safety with LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T2DM: the ELEMENT 2 study [abstract 64-OR]. Diabetes 2014;63(Suppl 1):A17.
-
(2014)
Diabetes
, vol.63
, pp. A17
-
-
Rosenstock, J.1
Hollander, P.2
Bhargava, A.3
-
57
-
-
84928559115
-
Comparative pharmacokinetics and pharmacodynamics of two insulin glargine products, LY2963016 and Lantus®, in healthy subjects at two dose levels
-
[abstract 890-P]
-
Zhang X, Chen Quin Lam E, Seger ME, et al.: Comparative pharmacokinetics and pharmacodynamics of two insulin glargine products, LY2963016 and Lantus®, in healthy subjects at two dose levels [abstract 890-P]. Diabetes 2014;63(Suppl 1):A227.
-
(2014)
Diabetes
, vol.63
, pp. A227
-
-
Zhang, X.1
Chen Quin-Lam, E.2
Seger, M.E.3
-
58
-
-
84872050633
-
Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A metaanalysis
-
Nanda KS, Cheifetz AS, Moss AC: Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a metaanalysis. Am J Gastroenterol 2013;108:40-47.
-
(2013)
Am J Gastroenterol
, vol.108
, pp. 40-47
-
-
Nanda, K.S.1
Cheifetz, A.S.2
Moss, A.C.3
-
59
-
-
53249142132
-
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study
-
Drucker DJ, Buse JB, Taylor K, et al.: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-1250.
-
(2008)
Lancet
, vol.372
, pp. 1240-1250
-
-
Drucker, D.J.1
Buse, J.B.2
Taylor, K.3
-
60
-
-
84860250733
-
Clinical relevance of anti-exenatide antibodies: Safety, efficacy and cross-reactivity with long-term treatment
-
Fineman MS, Mace KF, Diamant M, et al.: Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012;14:546-554.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 546-554
-
-
Fineman, M.S.1
Mace, K.F.2
Diamant, M.3
|